{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:12Z","timestamp":1787841312316,"version":"build-2784847793"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Von Willebrand disease (VWD) is a bleeding disorder that results from decreased von Willebrand factor (VWF) activity &lt;0.30 iu\/mL. Therefore, the diagnosis of type 3 VWD in patients with bleeding requires finding a VWF:Ag and\/or VWF:platelet ristocetin cofactor (RiCof) &lt;0.03 iu\/mL, no further testing is usually necessary. This is a cohort study that included 64 patients with type 3 VWD who were presented and diagnosed at the National Center of Hematology (NCH) from October 2014 to October 2016. In this study the sensitivity of VWF:Ag is only 78%, the sensitivity of VWF:RiCof is 92% of diagnosed cases. From our results it can be concluded that patients with type 3 VWD are usually presented with moderate\/severe mucocutaneous bleeding that is associated with prolonged bleeding time test of &gt;10 min and a family history of similar type of bleeding. This fact was frequently utilized to provisionally diagnose several members of the same family, forming a cohort of patients that is larger than the number of objectivelydiagnosed patients included in this study, when they cannot afford to be all tested with VWF:Ag\/VWF:RiCof.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T21:22:54Z","timestamp":1530566574000},"page":"211-214","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Presentation and diagnosis of patients with type 3 von Willebrand disease in resourceslimited laboratory"],"prefix":"10.4103","volume":"12","author":[{"given":"Abbas Hashim","family":"Abdulsalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusra","family":"Ghiath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhal","family":"Alrahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2018.05.006_b0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hemonc.2018.05.006_b0010","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2018.05.006_b0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/jth.12130","article-title":"The genetics of Canadian type 3 von Willebrand disease: further evidence for codominant inheritance of mutant alleles","volume":"11","author":"Bowman","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.hemonc.2018.05.006_b0020","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1538-7836.2009.03499.x","article-title":"Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire","volume":"7","author":"Bowman","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.hemonc.2018.05.006_b0025","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1538-7836.2010.03846.x","article-title":"Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire","volume":"8","author":"Biss","year":"2010","journal-title":"J Thromb Haemost"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387618300621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387618300621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2018.05.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:14Z","timestamp":1787838554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2018.05.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2018.05.006","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}